Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
暂无分享，去创建一个
E. Frangou | M. Stockler | M. Parmar | L. Pickering | P. Nathan | J. Bellmunt | I. Davis | B. Escudier | Janet E Brown | G. Stewart | G. Hermann | A. Bex | S. Joniau | R. McMenemin | J. Larkin | T. Eisen | L. Albiges | R. Kaplan | A. Ritchie | A. Meade | B. Hancock | J. Barber | E. Hodgkinson | B. Oza | Benjamin Smith | Benjamin Smith | R. Mcmenemin